The team at POPS! Diabetes Care, Inc. has plenty of reason to celebrate this summer. They recently closed an oversubscribed Series A funding of $6 Million, with incredible investor demand. Their product, a digital system which allows users to track and manage their A1C and insulin levels through an app and connected monitoring device, is making major waves in the healthcare space. FDA approval was reached in November of 2018, and in preliminary clinical research, their product demonstrated a 1-point drop in overall A1C for users.
The simplicity and ease of use of their system, combined with such substantial outcomes, is why funders are clamoring to invest in this innovative product. The POPS! team has been attending conferences nationwide, and are being met with excitement and buy-in from employers, insurers, and HR departments.
The team that develops for POPS! is personally committed to ensuring their product’s excellence. Their developer and management teams are comprised of people living with diabetes, which gives them meaningful insight for product development, and helps to ensure a good experience for users.